Formulating Poorly Water Soluble Drugs

  • Robert O. Williams III
  • Alan B. Watts
  • Dave A. Miller

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 22)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Zachary Warnken, Hugh D. C. Smyth, Robert O. Williams III
    Pages 1-39
  3. Daniel Ellenberger, Kevin P. O’Donnell, Robert O. Williams III
    Pages 41-120
  4. Justin R. Hughey, Siyuan Huang, Robert O. Williams III
    Pages 121-163
  5. Javier O. Morales, Alan B. Watts, Jason T. McConville
    Pages 165-213
  6. Soraya Hengsawas Surasarang, Robert O. Williams III
    Pages 215-256
  7. Youssef W. Naguib, Hannah L. O’Mary, Zhengrong Cui, Alan B. Watts
    Pages 257-293
  8. Justin LaFountaine, Ping Gao, Robert O. Williams III
    Pages 295-327
  9. Susanne Page, Reto Maurer, Nicole Wyttenbach
    Pages 329-382
  10. Abbe Haser, James C. DiNunzio, Charlie Martin, James W. McGinity, Feng Zhang
    Pages 383-435
  11. Dave A. Miller, Daniel Ellenberger, Marco Gil
    Pages 437-525
  12. Soraya Hengsawas Surasarang, Robert O. Williams III
    Pages 527-607
  13. Julien Maincent, Robert O. Williams III
    Pages 609-689
  14. Leena Kumari Prasad, Justin R. Hughey, James W. McGinity, Dave A. Miller, Robert O. Williams III
    Pages 691-740
  15. Back Matter
    Pages 769-779

About this book


The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop


bioavailability lipophilic solubility dissolution formulation development nanoparticle processes amorphous systems drug delivery route-specific challenges

Editors and affiliations

  • Robert O. Williams III
    • 1
  • Alan B. Watts
    • 2
  • Dave A. Miller
    • 3
  1. 1.Division of Pharmaceutics, College of PharmacyThe University of Texas at AustinAustinUSA
  2. 2.Division of Pharmaceutics, College of PharmacyThe University of Texas at AustinAustinUSA
  3. 3.DisperSol Technologies, LLCGeorgetownUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods